Check What Authors Claimed

 Quick Explanation Copied

 Long Explanation

Career Profile and Citation Metrics

OpenAlex records 44 works with ~2,200 citations and an h-index of 20 for Natalie Porat-Shliom, a NIH intramural investigator. Her citation trajectory peaked in 2009 and 2019 (203 and 456 citations/year, respectively), driven by early endocytosis work and the 2019 Nature Cell Biology paper on YAP phase separation (418 citations) YAP phase separation paper. Foundational first-author work on clathrin-independent endocytosis (H-Ras trafficking, 2007; CIE cargo discovery, 2009) and reviews on intravital microscopy and regulated exocytosis (2012–2013) form the bulk of her citation base CIE cargo discovery paper. Output remains active (4 works in 2025, 4 in 2026), with near-complete open access.

Recent First/Senior Work: Mechanistic Quality and Gaps

Two exemplar studies illustrate her scientific strength. The 2026 FLOT2/T-DM1 preprint combines orthogonal interaction assays (PLA, co-IP in three cell systems), five-line dose-response data, mechanistic epistasis (Cbl dependence, TAK-243 blockade), and a druggable repurposing candidate (zoledronic acid) with a specificity control (PHB1/2 knockdown fails to mimic), plus retrospective Caris clinical correlation. Reported IC50 shifts are large and consistent (e.g., HCC202: 125.2 to 9.5 ng/mL) FLOT2 ADC study. Limitations are real: no in vivo animal data, knockdown off-target risk, and weak clinical statistics (T-DM1 OS p=0.1; T-DXd p=0.04 in a retrospective, industry-held dataset lacking full transparency).

The 2016 Hepatology LKB1 study demonstrates in vivo rigor via intravital microscopy, TEM, and functional permeability tracers (3 kDa dextran entering canaliculi within ~2 minutes in knockouts), but sample sizes are small (n=3–4 per group for imaging), there are no rescue experiments, and causality beyond correlation is acknowledged as incomplete LKB1 in vivo liver study.

Critical Assessment

Strengths: consistent use of orthogonal, quantitative imaging-based methods; translation from endocytosis mechanobiology to hepatology to oncology shows conceptual breadth; transparent limitation statements; intramural NIH funding reduces financial-incentive bias, though the Caris partnership introduces a data-access opacity bias. Blindspots: clinical claims rest on retrospective, single-vendor real-world data; key mechanistic papers (YAP phase separation) are collaborative middle-authorships, so independent high-impact first/senior contributions are narrower; several in vivo datasets are underpowered (n=3–4), a common intravital-microscopy constraint. Falsifying the core FLOT2 mechanism would require failed Cbl/TAK-243 epistasis or null clinical association — criteria she explicitly defines, a rigor positive.

 BGPT Author Review

Scientific Quality

h-index 20 with ~2,200 citations over ~20 years reflects a solid, mid-career investigator, not a citation outlier. Her best work combines quantitative imaging, genetic models, and orthogonal validation; however, small in vivo sample sizes (n=3-4), absence of rescue experiments, and reliance on retrospective industry-held clinical data cap the score. Mechanistic epistasis (Cbl/TAK-243) is a rigor strength.

Communication Quality

Reviews and methodological papers (intravital microscopy primers, liver zonation) indicate clear pedagogical communication. Limitation statements are candid. Some works show variable knockdown efficiency and limited quantitative reporting in figures, slightly reducing clarity.

Author Novelty

Early identification of CIE cargo and H-Ras trafficking was field-shaping; the FLOT2-HER2 endocytosis-regulation axis and zoledronic acid repurposing are genuinely new angles on ADC biology, though the approach (knockdown + uptake assay) is conventional.

Scientific Rigor

Predefined falsification criteria, negative controls (PHB1/2), orthogonal assays, and triplicate experiments are strong. Weaknesses: no in vivo validation for the FLOT2 work, retrospective clinical statistics borderline (p=0.04/0.1), small imaging cohorts, and acknowledged off-target siRNA risk.